BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Author:
Sahin UgurORCID, Muik AlexanderORCID, Vogler IsabelORCID, Derhovanessian Evelyna, Kranz Lena M.ORCID, Vormehr MathiasORCID, Quandt JasminORCID, Bidmon Nicole, Ulges Alexander, Baum Alina, Pascal Kristen E.ORCID, Maurus DanielORCID, Brachtendorf Sebastian, Lörks VerenaORCID, Sikorski Julian, Koch PeterORCID, Hilker RolfORCID, Becker DirkORCID, Eller Ann-Kathrin, Grützner Jan, Tonigold Manuel, Boesler Carsten, Rosenbaum Corinna, Heesen Ludwig, Kühnle Marie-CristineORCID, Poran AsafORCID, Dong Jesse Z.ORCID, Luxemburger UlrichORCID, Kemmer-Brück Alexandra, Langer David, Bexon MartinORCID, Bolte Stefanie, Palanche Tania, Schultz Armin, Baumann Sybille, Mahiny Azita J.ORCID, Boros GáborORCID, Reinholz JonasORCID, Szabó Gábor T.ORCID, Karikó KatalinORCID, Shi Pei-YongORCID, Fontes-Garfias CamilaORCID, Perez John L., Cutler Mark, Cooper David, Kyratsous Christos A.ORCID, Dormitzer Philip R.ORCID, Jansen Kathrin U., Türeci Özlem
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Reference53 articles.
1. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020). 2. Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 383, 2439–2450 (2020). 3. Dagan, N. et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 384, 1412–1423 (2021). 4. Amit, S., Regev-Yochay, G., Afek, A., Kreiss, Y. & Leshem, E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet 397, 875–877 (2021). 5. Petter, E. et al. Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2. Preprint at https://doi.org/10.1101/2021.02.08.21251329 (2021).
Cited by
604 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|